HN02-40
A Single Arm Phase II Trial of Docetaxel and Capecitabine for the First Line Treatment of Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and […]
A Single Arm Phase II Trial of Docetaxel and Capecitabine for the First Line Treatment of Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and […]
A single arm, multi-center Phase 2 trial of mFOLFOX6 + trastuzumab + avelumab in first-line, metastatic, HER2-amplified gastric and esophageal adenocarcinoma
Phase II Trial of Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer (PLANE-PC) Status: Open to Accrual
Following is a cumulative list of Hoosier Cancer Research Network publications in germ cell tumors.
Phase 2 study of novel SEQUEnced immunotherapy (pembrolizumab) with anti-angiogenesis and chemotherapy in advanced gastric and gastroesophageaL junction (GEJ) adenocarcinoma (SEQUEL) Status: Open to Accrual
Rutgers Cancer Institute of New Jersey, first called “The Cancer Institute of New Jersey,” was born in 1993, became a National Cancer Institute (NCI) -designated […]
The Hoosier Cancer Research Network multi-center BRE12-158 study on triple-negative breast cancer (TNBC), led by Indiana University Melvin and Bren Simon Comprehensive Cancer Center, was […]
This month, Hoosier Cancer Research Network features our member institution The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard […]
This month, Hoosier Cancer Research Network features our member institution University of North Carolina Lineberger Comprehensive Cancer Center and Joshua F. Zeidner, MD, associate professor […]
A Phase II Trial of Avelumab or Hydroxychloroquine with or without Palbociclib to Eliminate Dormant Breast Cancer (“PALAVY”) Status: Open to Accrual
Results from a multi-site clinical trial for patients with triple-negative breast cancer (TNBC) show that genomic testing for circulating tumor DNA (ctDNA) and circulating tumor […]
This month, Hoosier Cancer Research Network features our member institution UT Southwestern Harold C. Simmons Comprehensive Cancer Center in Dallas, Texas, and Hans Hammers, MD, […]
Hoosier Cancer Research Network investigators recently presented an abstract during the 2022 Gastrointestinal Cancers Symposium. The abstract included an online poster session featuring HCRN […]
Hoosier Cancer Research Network investigators will present their findings from the HCRN GU16-260 study during the 2022 American Society of Clinical Oncology Genitourinary Cancer Symposium […]
Hoosier Cancer Research Network urothelial cancer study was highlighted during the 2023 ASCO Genitourinary Cancers Symposium in San Francisco. In a poster and rapid abstract […]
Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (ARCITECT) Status: Open to Accrual
A phase II study for adults with extensive-stage small cell lung cancer is testing the hypomethylating agent guadecitabine combined with the platinum-based chemotherapy drug carboplatin. […]
Hepatocellular carcinoma is an aggressive cancer that is often difficult to treat due to the typical accompanying diagnosis of cirrhosis. For patients who qualify for […]
This month, Hoosier Cancer Research Network (HCRN) features our member The University of Chicago Medicine Comprehensive Cancer Center, and Peter H. O’Donnell, MD, deputy director, […]
Website: University of New Mexico Comprehensive Cancer Center
Facebook
Hoosier Cancer Research Network on Facebook
Linked In
You Tube
Twitter